Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new ...

The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in ...

Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results ...

“Recovery Brands has been a trusted digital front door to treatment for millions, and this strategic sale enables Recovery.com to scale that impact even further—while allowing AAC to sharpen its focus ...

As WeightWatchers evolves its holistic model of care, community will continue to play an increasingly vital role, given its impact on long-term health outcomes and sustained behavioral change. In this ...

CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- SurgiBox, a medical technology company committed to improving access to safe, clean surgery at the point of need, announced today it has received ...

“These results represent a significant milestone for PALI-2108,” said JD Finley, Chief Executive Officer of Palisade Bio. “The early clinical activity, targeted delivery, dose flexibility, the ...

Royalty revenue was $1,378 million in the first six months of 2025 compared to $1,111 million in the first six months of 2024, an increase of $267 million, or 24%. The increase in royalties was driven ...

SOUTH JORDAN, Utah, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the Prelude ...

Shineco, Inc. (Nasdaq:SISI) ("Shineco" or the "Company"), a provider of innovative diagnostic medical products and related medical devices, today announced that the Company's Board of Directors has ...

Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable October 31, 2025, to shareholders of record at the close of business on September ...

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only ...